DE69627091D1 - N-(2-substituierte-3-(2-aminoethyl)-1H-indol-5-yl)-amide als 5-HT1F Agonisten - Google Patents

N-(2-substituierte-3-(2-aminoethyl)-1H-indol-5-yl)-amide als 5-HT1F Agonisten

Info

Publication number
DE69627091D1
DE69627091D1 DE69627091T DE69627091T DE69627091D1 DE 69627091 D1 DE69627091 D1 DE 69627091D1 DE 69627091 T DE69627091 T DE 69627091T DE 69627091 T DE69627091 T DE 69627091T DE 69627091 D1 DE69627091 D1 DE 69627091D1
Authority
DE
Germany
Prior art keywords
indol
aminoethyl
amides
substituted
ht1f agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69627091T
Other languages
English (en)
Other versions
DE69627091T2 (de
Inventor
James Erwin Fritz
Patric James Hahn
Stephen Warren Kaldor
Miles Goodman Siegel
Yao-Chang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69627091D1 publication Critical patent/DE69627091D1/de
Publication of DE69627091T2 publication Critical patent/DE69627091T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
DE69627091T 1995-10-10 1996-10-09 N-(2-substituierte-3-(2-aminoethyl)-1H-indol-5-yl)-amide als 5-HT1F Agonisten Expired - Fee Related DE69627091T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US521395P 1995-10-10 1995-10-10
US1585196P 1996-05-22 1996-05-22

Publications (2)

Publication Number Publication Date
DE69627091D1 true DE69627091D1 (de) 2003-05-08
DE69627091T2 DE69627091T2 (de) 2003-12-18

Family

ID=26674078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69627091T Expired - Fee Related DE69627091T2 (de) 1995-10-10 1996-10-09 N-(2-substituierte-3-(2-aminoethyl)-1H-indol-5-yl)-amide als 5-HT1F Agonisten

Country Status (9)

Country Link
US (3) US5942536A (de)
EP (1) EP0768301B1 (de)
JP (1) JPH11513666A (de)
AT (1) ATE236122T1 (de)
AU (1) AU7261196A (de)
CA (1) CA2234166A1 (de)
DE (1) DE69627091T2 (de)
ES (1) ES2194960T3 (de)
WO (1) WO1997013512A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
WO1998015545A1 (en) * 1996-10-08 1998-04-16 Eli Lilly And Company New serotonin 5-ht1f agonists
ES2212814T3 (es) * 1996-10-31 2004-08-01 Harbor Branch Oceanographic Institution, Inc. Uso de compuestos y composiciones antiinflamatorias neurogenicas.
WO1998047868A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
US6128537A (en) * 1997-05-01 2000-10-03 Medtronic, Inc Techniques for treating anxiety by brain stimulation and drug infusion
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US5905084A (en) * 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
FR2792313A1 (fr) * 1999-04-13 2000-10-20 Synthelabo Derives de 2-aminoethyl-indole, leur preparation et leur application en therapeutique
IL130169A (en) * 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
DE19963178A1 (de) * 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituierte Indol-Mannichbasen
BR0206595A (pt) * 2001-01-30 2004-07-13 Lilly Co Eli Composto, composição farmacêutica, e uso de um composto
CA2357114C (en) * 2001-03-22 2010-06-29 Pooger Properties Ltd. Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
JP4264689B2 (ja) * 2001-06-05 2009-05-20 ダイキン工業株式会社 酸の分離方法
AU2002346403A1 (en) * 2001-11-16 2003-06-10 University And Community College System Of Nevada On Behalf Of The University Of Nevada, Reno Method for selective conjugation of analytes to enzymes without unwanted enzyme-enzyme cross-linking
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
JP2006505571A (ja) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
WO2004041781A1 (en) * 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones
DE10254596A1 (de) * 2002-11-22 2004-06-03 Merck Patent Gmbh Indolderivate
ES2388547T3 (es) * 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
ES2291978T3 (es) 2003-12-17 2008-03-01 Eli Lilly And Company Compuestos de (4-aminociclohexen-1-il)fenilo y (4-aminociclohexen-1-il)piridinilo sustituidos como agonistas de 5-ht1f.
US7403118B2 (en) * 2005-11-29 2008-07-22 Checkpoint Systems, Inc. Security device with perimeter alarm
EP1953153A1 (de) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituierte Sulfonamide für die Behandlung von Wahrnehmungsstörungen bzw. Ernährungserkrankungen
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
ES2570452B1 (es) * 2014-10-15 2017-04-19 Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US3591603A (en) * 1968-05-13 1971-07-06 Little Inc A 3(3-indole) - lower-alkylamines
US3915990A (en) * 1973-03-13 1975-10-28 Nelson Res & Dev Tryptamines
US3903084A (en) * 1974-02-11 1975-09-02 Upjohn Co Carboximidoyl urea derivatives
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
US4544663A (en) * 1984-05-07 1985-10-01 Sandoz, Inc. Indolamine derivatives as anti-fertility agents
US5030640A (en) * 1989-01-05 1991-07-09 Merck & Co., Inc. Novel β-adrenergic agonists and pharmaceutical compositions thereof
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2064815C (en) * 1990-06-07 1999-11-16 Alan Duncan Robertson Therapeutic heterocyclic compounds
DE4026614A1 (de) * 1990-08-23 1992-02-27 Bayer Ag Phosphonopyrrolidin- und piperidin-haltige pseudopeptide vom statintyp, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (de) * 1991-02-12 1995-11-21 Pfizer
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
HUT69705A (en) * 1991-11-25 1995-09-28 Pfizer Indole derivatives
IL106445A (en) * 1992-07-30 1998-01-04 Merck Sharp & Dohme History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them
TW251284B (de) * 1992-11-02 1995-07-11 Pfizer
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
DE4321366A1 (de) * 1993-06-26 1995-01-05 Merck Patent Gmbh Piperidine und Piperazine
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
US5439918A (en) * 1994-03-14 1995-08-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5962815A (en) * 1995-01-18 1999-10-05 Prolinx Labs Corporation Antifuse interconnect between two conducting layers of a printed circuit board
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
WO1998015545A1 (en) * 1996-10-08 1998-04-16 Eli Lilly And Company New serotonin 5-ht1f agonists

Also Published As

Publication number Publication date
CA2234166A1 (en) 1997-04-17
US5942536A (en) 1999-08-24
ATE236122T1 (de) 2003-04-15
DE69627091T2 (de) 2003-12-18
WO1997013512A1 (en) 1997-04-17
EP0768301B1 (de) 2003-04-02
ES2194960T3 (es) 2003-12-01
AU7261196A (en) 1997-04-30
JPH11513666A (ja) 1999-11-24
US6126932A (en) 2000-10-03
US5998630A (en) 1999-12-07
EP0768301A1 (de) 1997-04-16

Similar Documents

Publication Publication Date Title
DE69627091T2 (de) N-(2-substituierte-3-(2-aminoethyl)-1H-indol-5-yl)-amide als 5-HT1F Agonisten
ATE253063T1 (de) 5-ht1f-agonisten
PT1671949E (pt) Piridinilaminas substituídas
IL114474A (en) (R)-(3)-3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)acetylamino]-2-[N-(2-(4-piperidin-1-yl)piperidin-1-yl acetyl)amino]propane dihydrochloride trihydrate and tachykinin receptor antagonistic pharmaceutical compositions containing it
DE69903992T2 (de) Heterocyclische Carboxamide
DE69319976D1 (de) 7-Substituierte-9-substituierte Glycylamido-6-Demethyl-6-Deoxytetracycline
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
DE69625518T2 (de) Wirkstoff zur behandlung neurodegenerativer störungen
ATE240953T1 (de) Carbazolcarboxamide als 5-ht1f agonisten
DE69626981D1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
ATE256678T1 (de) 4-(2-pyridyl)piperazine als agonisten des 5ht7 rezeptors
NO20002408D0 (no) 5-HT1F antagonister
ATE190617T1 (de) Substituierte 4-(6-fluor-(1h)-indol-3-yl)1,2,3,6- tetrahydropyridin-derivate für die behandlung von zns-störungen
PT950056E (pt) N-(piridinilamino) isoindolinas e compostos relacionados
ES2139714T3 (es) Fluororribosil-aminas anomericas.
CA2044186A1 (fr) Nouveau procede de preparation industrielle du 4-chloro 3-sulfamoyl n-(2,3-dihydro 2-methyl 1h-indol-1-yl) benzamide a partir du 2,3-dihydro 2-methyl 1h-indole et de l'acide hydroxylamine-0-sulfonique
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
FR2783172B1 (fr) Produit contenant du lait d'equides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee